[1] Rasmussen S A, Gerber S I, Swerdlow D L. Middle East respiratory syndrome coronavirus: update for clinicians[J]. Clin Infect Dis, 2015,60(11):1686-1689.
[2] Zumla A, Hui D S, Perlman S. Middle East respiratory syndrome[J].Lancet,2015,S0140-6736(15):60454-60458.
[3] Zaki A M, Van Boheemen S, Bestebroer T M, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia[J]. N Engl J Med, 2012, 367(19): 1814-1820.
[4] De Groot R J, Baker S C, Baric R S, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group[J]. J Virol, 2013, 87(14): 7790-7792.
[5] Banik G R, Khandaker G, Rashid H. Middle East respiratory syndrome coronavirus "MERS-CoV": current knowledge gaps[J].Paediatr Respir Rev,2015,16(3):197-202.
[6] Hui D S, Perlman S, Zumla A. Spread of MERS to South Korea and China[J]. Lancet Respir Med, 2015, 3(7): 509-510.
[7] Gostin L O, Lucey D. Middle East respiratory syndrome: a global health challenge[J]. JAMA, 2015,314(8):771-772.
[8] Alsolamy S. Middle East respiratory syndrome: knowledge to date[J].Crit Care Med, 2015, 43(6): 1283-1290.
[9] Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design[J]. FEBS J, 2014, 281(18): 4085-4096.
[10] Van der Hoek L. Human coronaviruses: what do they cause?[J].Antivir Ther, 2007,12(4 Pt B): 651-658.
[11] Van der Hoek L, Sure K, Ihorst G, et al. Croup is associated with the novel coronavirus NL63[J].PLoS Med,2005,2(8):e240.
[12] Van Boheemen S, De Graaf M, Lauber C, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans [J]. mBio, 2012, 3(6): 473-485.
[13] Guery B, Poissy J, Mansouf L, et al. Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus: a report of nosocomial transmission[J]. Lancet, 2013, 381(9885): 2265-2272.
[14] Arabi Y M, Arifi A A, Balkhy H H, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection[J]. Ann Intern Med, 2014, 160(6): 389-397.
[15] Al-Abdallat M M, Payne D C, Alqasrawi S, et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description[J]. Clin Infect Dis, 2014, 59(9): 1225-1233.
[16] Drosten C, Muth D, Corman V M, et al. An observational, laboratory-based study of outbreaks of Middle East respiratory syndrome coronavirus in Jeddah and Riyadh, Kingdom of Saudi Arabia, 2014[J]. Clin Infect Dis, 2015, 60(3): 369-377.
[17] Sampathkumar P. Middle East respiratory syndrome: what clinicians need to know [J]. Mayo Clin Proc, 2014,89(8):1153-1158.
[18] Memish Z A, Zumla A I, Al-Hakeem R F, et al. Family cluster of Middle East respiratory syndrome coronavirus infections[J]. N Engl J Med, 2013, 368(26): 2487-2494.
[19] Munster V J, de Wit E, Feldmann H. Pneumonia from human coronavirus in a macaque model [J]. N Engl J Med, 2013, 368(16): 1560-1562.
[20] Van den Brand J M, Smits S L, Haagmans B L. Pathogenesis of Middle East respiratory syndrome coronavirus[J]. J Pathol, 2015, 235(2): 175-184.
[21] Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study[J].J Antimicrob Chemother,2015,70(7):2129-2132.
[22] Ajlan A M, Ahyad R A, Jamjoom L G, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings[J].Am J Roentgenol, 2014, 203(4): 782-787.
[23] Das K M, Lee E Y, Jawder S E, et al. Acute Middle East respiratory syndrome coronavirus: temporal lung changes observed on the chest radiographs of 55 patients[J]. Am J Roentgenol, 2015,205(3): W267-S274.
[24] Eckerle I, Muller M A, Kallies S, et al. In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East respiratory syndrome (MERS) coronavirus infection[J]. Virol J, 2013, 10: 359.
[25] Chan J F, Lau S K, To K K, et al. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease[J]. Clin Microbiol Rev, 2015, 28(2): 465-522.
[26] Corman V M, Eckerle I, Bleicker T, et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction [J]. Euro Surveill, 2012, 17(39): 20285.
[27] Lu X, Whitaker B, Sakthivel S K, et al. Real-time reverse transcription-PCR assay panel for Middle East respiratory syndrome coronavirus[J]. J Clin Microbiol, 2014, 52(1): 67-75.
[28] Chan K H, Chan J F, Tse H, et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests [J]. J Infect, 2013, 67(2): 130-140.
[29] Zumla A, Hui D S. Infection control and MERS-CoV in health-care workers[J]. Lancet, 2014, 383(9932): 1869-1871.
[30] Wray R J, Becker S M, Henderson N, et al. Communicating with the public about emerging health threats: lessons from the Pre-Event Message Development Project [J]. Am J Public Health, 2008, 98(12): 2214-2222.
[31] Momattin H, Mohammed K, Zumla A, et al. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy[J]. Int J Infect Dis, 2013, 17(10): e792-798.
[32] Falzarano D, De Wit E, Martellaro C, et al. Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin[J]. Sci Rep, 2013, 3: 1686.
[33] Hart B J, Dyall J, Postnikova E, et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays [J]. J Gen Virol, 2014, 95(Pt 3): 571-577.
[34] Falzarano D, De Wit E, Rasmussen AL, et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques [J]. Nat Med, 2013, 19(10): 1313-1317.
[35] Omrani A S, Saad M M, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study [J]. Lancet Infect Dis, 2014, 14(11): 1090-1095.
[36] Al-Tawfiq J A, Momattin H, Dib J, et al. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study [J]. Int J Infect Dis, 2014, 20: 42-46.
[37] Mair-Jenkins J, Saavedra-Campos M, Baillie J K, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis[J]. J Infect Dis, 2015, 211(1): 80-90.
[38] Stockman L J, Bellamy R, Garner P. SARS: systematic review of treatment effects [J]. PLoS Med, 2006, 3(9): e343.
[39] Kucharski A J, Althaus C L. The role of superspreading in Middle East respiratory syndrome coronavirus (MERS-CoV) transmission[J]. Euro Surveill, 2015, 20(25):14-18.
[40] Petersen E, Hui D S, Perlman S, et al. Middle East Respiratory Syndrome-advancing the public health and research agenda on MERS-lessons from the South Korea outbreak[J]. Int J Infect Dis, 2015,6(36):54-55.